Healthcare IT News sharing our fundraising announcement today:
Hexoskin, a Montreal-based digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, is very excited to announce today an additional USD $4.2M capital raise to invest in growth, digital biomarkers research, and new AI-based digital diagnostics solutions. Investors include AQC Capital and Anges Quebec (Canada), BDC Capital (Canada), ballas invest (Europe), Deep Divers Ltd (UK), and 19 other US and Canadian private investors.
Pierre-Alexandre Fournier, Hexoskin’s CEO, commented, “Hexoskin’s team has over 15 years of experience in clinical AI development and high-resolution wearable sensors. Our investors understand how our digital platform is uniquely positioned to develop a range of diagnostic tests and digital solutions that can address the needs of large populations in disease areas with large unmet needs, such as cardiac, respiratory, and rare diseases.”
Hexoskin’s current wearable sensing products (Hexoskin & Astroskin) serve the clinical research, defense, and aerospace markets. Its customers, including CSA, NASA, DOD, Yale Health, Boston Children’s Hospital, and hundreds of research teams across the world, have published over 250 scientific papers with Hexoskin data. Hexoskin smart shirts are also used in pharma clinical trials, and its technology has been part of the International Space Station since 2019 to support clinical trials in space.
“We are excited to team up with Hexoskin and its investors to enable its next phase of development globally,” said Laurent van Lerberghe, Co-Founder of ballas invest and former Chief Strategy Officer at Sanofi. “We have been impressed by the wealth of expertise accumulated by Hexoskin with trillions of data points, more than a hundred clinical trials, and over 250 peer-reviewed publications. Through novel higher resolution digital measures and digital biomarkers in clinical and real-world settings, Hexoskin is unlocking the possibilities of early disease detection and high-quality monitoring, hence improving treatment decisions and patients’ quality of life.”
More information about the company and the announcement here:
https://lnkd.in/gmDfyHbr